Inzoomen: druk op uw toetsenbord op CtrlCommand + +
Uitzoomen: druk op uw toetsenbord op CtrlCommand + -
Gebruik knijpzoomen om eenvoudig in en uit te zoomen

OB-SNP study

Laatste wijziging: 12 januari 2022

Genetic polymorphisms related to atypical antipsychotics induced weight gain

 

Principal Investigator: Prof. Dr. Guy Massa

 

This cross-sectional study includes a physiogenomic analysis of single nucleotide polymorphisms (SNPs) in candidate genes that might be associated with atypical antipsychotic (AAP)-induced weight gain, appetite regulation and obesity.

 

The purpose of this study is to determine selected SNPs and to correlate these specific SNPs with weight gain in children and adolescents treated with Abilify® or Risperdal®.

 

Hundred patients will be questioned about their personal and family history and medication use. Height and weight will be measured to calculate BMI and compared with earlier BMI data to detect changes in weight under AAP-treatment. One blood sample will be collected. Buffy coat will be isolated and genomic DNA will be purified. Sixteen selected SNPs will be genotyped by real-time PCR using Taqman SNP Genotyping Assays. The obtained data will be statistically analyzed in association with CENSTAT (Hasselt University).

 

This study can extend the knowledge about underlying drug specific mechanisms and related metabolic side effects of Abilify® and Risperdal®. Subsequently, this information will lead to the capability to predict weight gain as a consequence of treatment with Abilify® or Risperdal® and could make it possible to limit weight gain, often leading to overweight or obesity, in a specific manner.